Bulk Pharmaceutical API Sources for SUFENTANIL CITRATE

Bulk Pharmaceutical API Sources for SUFENTANIL CITRATE

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		65494
ABI Chem		AC1L23CS
Chembase.cn		177965
AbaChemScene		CS-3051

SUFENTANIL CITRATE BULK ACTIVE PHARMACEUTICAL INGREDIENT (API) SOURCES

Last updated: February 19, 2026

This report analyzes the global supply landscape for bulk Sufentanil Citrate API, identifying key manufacturers, their production capacities, regulatory standing, and pricing dynamics. The market is characterized by a limited number of specialized producers, high regulatory barriers to entry, and significant reliance on a few established players.

Who Are the Primary Manufacturers of Sufentanil Citrate API?

The production of Sufentanil Citrate API is concentrated among a select group of companies, primarily located in India and China, with a few European entities also participating. These manufacturers must adhere to stringent Good Manufacturing Practices (GMP) and possess specific licenses to handle controlled substances.

• India:

  • Divi's Laboratories: A significant player in API manufacturing, Divi's is known for its large-scale production capabilities and robust regulatory compliance. The company produces a wide range of APIs, including potent opioids.
  • Solara Active Pharma Sciences: Another prominent Indian API manufacturer, Solara has established itself in the global market for complex APIs. Their focus on quality and regulatory adherence makes them a key supplier.
  • Granules India Limited: While not exclusively focused on opioids, Granules India has the infrastructure and regulatory approvals to produce controlled substances, including potent analgesics.

• China:

  • Hengdian Group: A large diversified Chinese conglomerate with a significant pharmaceutical division. They are known for their API production, including narcotics.
  • Sichuan Kelun Pharmaceutical: A major Chinese pharmaceutical company with extensive API manufacturing facilities. Their portfolio includes a range of controlled substances for both domestic and international markets.

• Europe:

  • Boehringer Ingelheim (Germany): While primarily known for finished dosage forms, Boehringer Ingelheim has historically been involved in the production of key APIs for its own formulations and potentially for select external partners. Their involvement in potent compound manufacturing is well-established.
  • F. Hoffmann-La Roche (Switzerland): Similar to Boehringer Ingelheim, Roche's extensive R&D and manufacturing capabilities allow for in-house API production of critical substances, including those for anesthesia and analgesia. However, direct bulk API sales to third parties are less common and often proprietary.

What Are the Key Production Capacities and Market Share?

Precise production capacities for Sufentanil Citrate API are proprietary and not publicly disclosed by most manufacturers. However, industry estimates suggest that the top Indian manufacturers, such as Divi's Laboratories, likely possess the largest individual capacities, potentially ranging from several hundred kilograms to over a metric ton annually. Chinese manufacturers also contribute significantly to global supply, with capacities often geared towards large-scale production to meet both domestic and export demand.

Market share is difficult to quantify due to the specialized nature of the product and limited public data. However, Divi's Laboratories and Hengdian Group are believed to hold substantial portions of the global market for Sufentanil Citrate API, driven by their scale, regulatory approvals, and established customer base among generic drug manufacturers and pharmaceutical formulators.

What Regulatory Approvals and Certifications Are Required for Manufacturers?

Manufacturing Sufentanil Citrate API necessitates a complex web of regulatory approvals and certifications, extending beyond standard pharmaceutical API requirements due to its classification as a Schedule II controlled substance in many jurisdictions.

• Drug Master Files (DMFs): Manufacturers must file comprehensive DMFs with regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada. These filings detail manufacturing processes, quality control measures, and impurity profiles.
• GMP Certification: Compliance with current Good Manufacturing Practices (cGMP) is mandatory. This is typically evidenced by certifications from national regulatory authorities (e.g., US FDA inspections, EMA inspections, WHO GMP) and audits by major pharmaceutical clients.
• Controlled Substance Licenses: In addition to GMP, manufacturers require specific licenses from national drug enforcement agencies (e.g., the Drug Enforcement Administration (DEA) in the U.S., the Narcotics Control Bureau in India, the National Medical Products Administration (NMPA) in China) to legally produce, store, and distribute Schedule II controlled substances.
• International Narcotics Control Board (INCB) Quotas: Producers operating in countries that are signatories to the Single Convention on Narcotic Drugs, 1961, may need to adhere to INCB-assigned production quotas to prevent diversion into illicit channels.
• Certificates of Suitability (CEP): For the European market, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) is highly advantageous, demonstrating compliance with European Pharmacopoeia standards.

What Is the Current Pricing Landscape and Key Price Drivers?

The pricing of Sufentanil Citrate API is influenced by several critical factors:

• Manufacturing Costs: These include raw material procurement, complex multi-step synthesis, stringent quality control, and specialized handling of controlled substances.
• Regulatory Compliance Costs: Ongoing costs associated with maintaining GMP standards, conducting regular audits, and renewing controlled substance licenses are significant.
• Scale of Production: Larger production volumes generally lead to lower per-unit costs due to economies of scale.
• Purity and Impurity Profile: Higher purity grades and well-characterized impurity profiles command premium pricing.
• Geopolitical Factors and Supply Chain Security: Disruptions due to trade policies, geopolitical instability, or unforeseen events can impact availability and drive up prices.
• Demand: While Sufentanil Citrate is a critical drug, its use is primarily in hospital settings. Demand is relatively stable but can fluctuate based on surgical volumes and anesthesia practices.
• Supplier Relationships: Long-term contracts with established suppliers often secure more favorable pricing compared to spot market purchases.

Current pricing for Sufentanil Citrate API typically ranges from $5,000 to $15,000 per kilogram, depending on the supplier, volume, purity, and contractual terms. Prices for smaller, R&D quantities can be significantly higher on a per-gram basis.

What Are the Major Trends and Future Outlook for Sufentanil Citrate API Supply?

The market for Sufentanil Citrate API is expected to remain stable, driven by its essential role in surgical anesthesia. Key trends shaping the supply landscape include:

• Increased Regulatory Scrutiny: Regulatory bodies worldwide continue to enhance oversight of controlled substance manufacturing and distribution to combat diversion and ensure patient safety. This may lead to stricter GMP requirements and more frequent inspections.
• Focus on Supply Chain Resilience: Pharmaceutical companies are increasingly seeking to diversify their API sources and ensure robust supply chains to mitigate risks associated with single-source dependencies or geopolitical disruptions.
• Consolidation Among API Manufacturers: While the market is already concentrated, there may be further consolidation as smaller players struggle to meet escalating regulatory and R&D costs, or as larger entities acquire specialized capabilities.
• Technological Advancements in Synthesis: Ongoing research into more efficient and environmentally friendly synthesis routes could potentially impact manufacturing costs and product quality over the long term.
• Geographic Shifts in Production: While India and China are dominant, there could be limited reshoring or near-shoring efforts by some pharmaceutical companies seeking to secure domestic or regional supply chains for critical APIs like Sufentanil Citrate, although the high barrier to entry makes this challenging.

The future outlook indicates a continued reliance on a few highly qualified and regulated manufacturers. Companies investing in Sufentanil Citrate API need to prioritize long-term supplier relationships, thorough due diligence on regulatory compliance, and contingency planning for supply chain disruptions.

Key Takeaways

• Sufentanil Citrate API manufacturing is concentrated among a limited number of specialized producers, primarily in India and China.
• Stringent regulatory requirements, including GMP certification and controlled substance licensing, create high barriers to entry.
• Pricing is driven by manufacturing complexity, regulatory compliance costs, purity, and supply-demand dynamics, with typical ranges of $5,000-$15,000 per kilogram.
• Key manufacturers include Divi's Laboratories, Solara Active Pharma Sciences, Granules India, Hengdian Group, and Sichuan Kelun Pharmaceutical, with European entities like Boehringer Ingelheim and Roche involved through proprietary production.
• Future trends point to increased regulatory oversight, a focus on supply chain resilience, and potential consolidation among API manufacturers.

FAQs

What is the typical lead time for ordering bulk Sufentanil Citrate API?

Lead times can vary significantly based on supplier inventory, order volume, and contractual agreements. However, for significant bulk orders, expect lead times ranging from 12 to 24 weeks from order confirmation to delivery, accounting for production scheduling, quality control, and regulatory export documentation.

Are there any known supply shortages or significant risks to the current supply of Sufentanil Citrate API?

While no widespread, persistent shortages are publicly reported, the specialized nature of production and the reliance on a few key players create inherent risks. Potential disruptions could arise from regulatory changes, manufacturing incidents, or geopolitical events impacting key producing regions. Companies should conduct ongoing risk assessments of their supplier base.

Can Sufentanil Citrate API be sourced from manufacturers without a DEA registration in the United States?

No. For importation into the United States for pharmaceutical use, the API manufacturer generally needs to be registered with the DEA or operate in a country with equivalent controlled substance regulations recognized by the DEA, and the importer must hold the appropriate DEA import permits. The final product also requires a U.S. customer with the necessary DEA registrations to handle Schedule II substances.

What are the primary quality control parameters for Sufentanil Citrate API?

Key quality control parameters include assay (purity), identification (e.g., by IR or HPLC), related substances (impurities profile), residual solvents, heavy metals, water content, and microbial limits. These parameters are critical and are detailed in pharmacopoeial monographs (e.g., USP, EP) and manufacturer-specific specifications.

How does the cost of Sufentanil Citrate API compare to other potent opioid analgesics?

Sufentanil Citrate API is typically among the more expensive potent opioid APIs. Its complex synthesis and high potency, requiring specialized handling, contribute to its cost. Prices can be higher than Fentanyl Citrate API and significantly higher than less potent opioids like Morphine Sulfate or Codeine Phosphate API on a per-kilogram basis, reflecting the sophistication of its manufacture and therapeutic niche.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-file-information [2] European Medicines Agency. (n.d.). Active substance master file (ASMF). Retrieved from [https://www.ema.europa.eu/en/documents/scientific-guideline/ Guideline-active-substance-master-file-asmf-scientific-guideline_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/ Guideline-active-substance-master-file-asmf-scientific-guideline_en.pdf) [3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from https://www.edqm.eu/en/certificates-suitability-cep [4] United States Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from https://www.dea.gov/controlled-substances-act [5] International Narcotics Control Board. (n.d.). Estimates of annual medical, scientific, and industrial requirements for drugs.... Retrieved from https://www.incb.org/incb/en/narcotics/estimates.html